CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 5.74: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
51.91BINR540.91M · vs all stocks (USD)
Trailing P/E
333.54xRevenue (TTM)
8.52BINR88.82M · vs all stocks (USD)
Profit Margin
3.46%Beta
0.4790xvs all stocks
52-Week Change
42.27%vs all stocks
Market Capitalization
51.91BINR540.91M · vs all stocks (USD)
Enterprise Value
66.38BINR691.75M · vs all stocks (USD)
Trailing P/E
333.54xForward P/E
25.33xPEG Ratio
-4.09xPrice to Sales (TTM)
6.33xPrice to Book (MRQ)
4.19xEnterprise to Revenue
7.79xEnterprise to EBITDA
109.34xGross Margin
32.83%Profit Margin
3.46%Operating Margin
1.00%Return on Assets (TTM)
0.44%Return on Equity (TTM)
0.64%Revenue (TTM)
8.52BINR88.82M · vs all stocks (USD)
Revenue per Share (TTM)
168.17INRUpdated Sep 29, 2026Quarterly Revenue Growth
75.90%Gross Profit (TTM)
3.06BINR31.84M · vs all stocks (USD)
EBITDA (TTM)
665.08MINR6.93M · vs all stocks (USD)
Net Income (TTM)
294.64MINR3.07M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-78.40%Operating Cash Flow (TTM)
1.26BINR13.09M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
99.59MINR1.04M · vs all stocks (USD)
5-Year Average Dividend Yield
3.01%vs all stocks
Payout Ratio
0.00%Revenue
8.11BINRFY2026 · Mar 31, 2026Cost of Goods Sold
5.26BINRFY2026 · Mar 31, 2026Gross Profit
2.85BINRFY2026 · Mar 31, 2026Operating Income
1.59BINR16.52M · vs all stocks (USD)
Pre-tax Income
210.17MINRFY2026 · Mar 31, 2026Income Tax Expense
-1.92MINRFY2026 · Mar 31, 2026Net Income
205.47MINRFY2026 · Mar 31, 2026EBIT
342.75MINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
763.02MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
132.59MINRFY2026 · Mar 31, 2026Net Income from Continuing Operations
203.55MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
589.62MINRFY2026 · Mar 31, 2026Free Cash Flow
-3.16BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
70.08MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
203.55MINRFY2026 · Mar 31, 2026Other Non-cash Items
48.56MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-140.94MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
478.44MINRFY2026 · Mar 31, 2026Capital Expenditures
-3.75BINRFY2026 · Mar 31, 2026Net Acquisitions
0.00INRFY2026 · Mar 31, 2026Net Investing Cash Flow
-3.75BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
-128.52MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-128.52MINRFY2026 · Mar 31, 2026Shares Outstanding
50.72MSharesUpdated Sep 29, 2026Float Shares
48.09MSharesUpdated Sep 29, 2026% Held by Insiders
59.15%vs all stocks
% Held by Institutions
17.25%vs all stocks
Total Cash (MRQ)
832.11MINR8.67M · vs all stocks (USD)
Total Cash per Share (MRQ)
13.94INRUpdated Sep 29, 2026Total Debt (MRQ)
3.63BINR37.79M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2816xCurrent Ratio (MRQ)
1.89xBook Value per Share (MRQ)
253.98INRUpdated Sep 29, 2026Total Assets
19.11BINR199.14M · vs all stocks (USD)
Total Current Assets
6.84BINRFY2026 · Mar 31, 2026Total Liabilities
6.23BINRFY2026 · Mar 31, 2026Total Non-current Assets
12.27BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
3.44BINRFY2026 · Mar 31, 2026Total Current Liabilities
2.79BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
70.08MINRFY2026 · Mar 31, 2026Other Short-term Investments
770.66MINRFY2026 · Mar 31, 2026Accounts Receivable
2.64BINRFY2026 · Mar 31, 2026Inventory
2.56BINRFY2026 · Mar 31, 2026Accounts Payable
2.30BINRFY2026 · Mar 31, 2026Short-term Debt
301.36MINRFY2026 · Mar 31, 2026Other Current Liabilities
187.99MINRFY2026 · Mar 31, 2026Long-term Debt
3.32BINRFY2026 · Mar 31, 2026Common Stock (Book)
507.19MINRFY2026 · Mar 31, 2026Total Shareholders' Equity
12.88BINR134.20M · vs all stocks (USD)
52-Week Low
480.00INRUpdated Sep 29, 202652-Week High
1.14KINRUpdated Sep 29, 202652-Week Change
42.27%vs all stocks
Beta
0.4790xvs all stocks
50-Day MA
1.00KINRUpdated Sep 29, 2026200-Day MA
789.88INRUpdated Sep 29, 2026Avg 10-Day Volume
179.10KSharesUpdated Sep 29, 2026Avg 30-Day Volume
112.51KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
3.19INRUpdated Sep 29, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.76Receivables vs revenue divergence: 2.21
Financial Health
Altman Z-Score 5.74: safe zoneNotable
Altman Z-Score: 5.74
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Pharmicell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Shen Lian Bio-Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Delcath Systems Inc.
Tier 1ProductionApproval-Gated PipelineRule
BrainsWay Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lifecome Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bliss GVS Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Kingchem Liaoning Life Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TaiMed Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhuhai Rundu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule